Management of Stable Coronary Artery Disease and Acute Coronary Syndrome in Patients with Cancer.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Cardiology Reports Pub Date : 2025-03-04 DOI:10.1007/s11886-025-02214-x

Shubh Desai, Moez Karim Aziz, Konstantinos Marmagkiolis, Mehmet Cilingiroglu, Cezar Iliescu, Leslie A Ynalvez

{"title":"Management of Stable Coronary Artery Disease and Acute Coronary Syndrome in Patients with Cancer.","authors":"Shubh Desai, Moez Karim Aziz, Konstantinos Marmagkiolis, Mehmet Cilingiroglu, Cezar Iliescu, Leslie A Ynalvez","doi":"10.1007/s11886-025-02214-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review examines the current evidence and management strategies for stable coronary artery disease (CAD) and acute coronary syndrome (ACS) in patients with cancer. We outline the unique challenges, optimal treatment approaches, and outcomes in this growing population.Recent findings: First-line medications for CAD management are consistently underutilized in cancer patients despite serving as standard of care. As a corollary, medical optimization in CAD management in general is less likely to occur in patients with cancer. Early invasive strategies in ACS show improved survival, yet cancer patients receive percutaneous coronary intervention less frequently than non-cancer patients. Optimization of medical management should be prioritized in stable CAD; revascularization with PCI is first line for most patients presenting with ACS. Modification of risk factors contributing to both CAD and cancer is of utmost importance. Cancer survivors should receive vigilant, long-term monitoring for the development of signs of CAD.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"65"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-025-02214-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review examines the current evidence and management strategies for stable coronary artery disease (CAD) and acute coronary syndrome (ACS) in patients with cancer. We outline the unique challenges, optimal treatment approaches, and outcomes in this growing population.

Recent findings: First-line medications for CAD management are consistently underutilized in cancer patients despite serving as standard of care. As a corollary, medical optimization in CAD management in general is less likely to occur in patients with cancer. Early invasive strategies in ACS show improved survival, yet cancer patients receive percutaneous coronary intervention less frequently than non-cancer patients. Optimization of medical management should be prioritized in stable CAD; revascularization with PCI is first line for most patients presenting with ACS. Modification of risk factors contributing to both CAD and cancer is of utmost importance. Cancer survivors should receive vigilant, long-term monitoring for the development of signs of CAD.

查看原文本刊更多论文

稳定性冠状动脉疾病和急性冠状动脉综合征在癌症患者中的处理。

综述目的：本综述探讨了稳定型冠状动脉疾病（CAD）和急性冠状动脉综合征（ACS）在癌症患者中的现有证据和治疗策略。我们概述了独特的挑战，最佳的治疗方法，并在这一不断增长的人口的结果。最近的研究发现：尽管作为标准治疗，但CAD治疗的一线药物在癌症患者中一直未得到充分利用。因此，CAD管理的医疗优化通常不太可能发生在癌症患者身上。ACS的早期侵入策略显示生存率提高，但癌症患者接受经皮冠状动脉介入治疗的频率低于非癌症患者。稳定型CAD应优先优化医疗管理；对于大多数ACS患者，PCI血运重建术是首选。改变导致冠心病和癌症的危险因素是至关重要的。癌症幸存者应该接受警惕的、长期的监测，以监测冠心病的体征发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Cardiology Reports CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.20

自引率

2.70%

发文量

209

期刊介绍： The aim of this journal is to provide timely perspectives from experts on current advances in cardiovascular medicine. We also seek to provide reviews that highlight the most important recently published papers selected from the wealth of available cardiovascular literature. We accomplish this aim by appointing key authorities in major subject areas across the discipline. Section editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.